(4S,7S,9aR)-7-[(2-methylpropan-2-yl)oxycarbonylamino]-6-oxo-1,2,3,4,7,8,9,9a-octahydroquinolizine-4-carboxylic acid | 481681-89-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S,7S,9aR)-7-[(2-methylpropan-2-yl)oxycarbonylamino]-6-oxo-1,2,3,4,7,8,9,9a-octahydroquinolizine-4-carboxylic acid
• CAS: 481681-89-4
• 化学式: C₁₅H₂₄N₂O₅
• 分子量: 312.366
• InChiKey: UDBCDCFDOCUJLK-VWYCJHECSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4S,7S,9aR)-7-[(2-methylpropan-2-yl)oxycarbonylamino]-6-oxo-1,2,3,4,7,8,9,9a-octahydroquinolizine-4-carboxylic acid 、 三甲基硅烷化重氮甲烷 以 甲醇 、 甲苯 为溶剂， 反应 0.08h， 以126 mg的产率得到methyl (4S,7S,9aR)-7-[(2-methylpropan-2-yl)oxycarbonylamino]-6-oxo-1,2,3,4,7,8,9,9a-octahydroquinolizine-4-carboxylate
  参考文献：
  名称：

  对映体纯肽模拟支架 2-Oxo-1-氮杂双环 [4.4.0] 癸烷的一种新的非对映选择性合成方法

  摘要：

  已开发出一种合成未取代和 C-7 取代的氮杂双环 [4.4.0] 癸烷二肽（23、30a 和 30b）的通用方法，它们可用作二肽模拟物。这种新方法的关键步骤涉及恶唑烷醛 5 和砜 7 的偶联反应，两者均来自 L-谷氨酸。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

  DOI：

  10.1002/ejoc.200400709
• 作为产物：
  描述：

  tert-butyl N-[(3S,6S,9aR)-6-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-oxo-1,2,3,6,7,8,9,9a-octahydroquinolizin-3-yl]carbamate 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochlorite 、 四丁基氟化铵 、 potassium bromide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 3.0h， 生成 (4S,7S,9aR)-7-[(2-methylpropan-2-yl)oxycarbonylamino]-6-oxo-1,2,3,4,7,8,9,9a-octahydroquinolizine-4-carboxylic acid
  参考文献：
  名称：

  对映体纯肽模拟支架 2-Oxo-1-氮杂双环 [4.4.0] 癸烷的一种新的非对映选择性合成方法

  摘要：

  已开发出一种合成未取代和 C-7 取代的氮杂双环 [4.4.0] 癸烷二肽（23、30a 和 30b）的通用方法，它们可用作二肽模拟物。这种新方法的关键步骤涉及恶唑烷醛 5 和砜 7 的偶联反应，两者均来自 L-谷氨酸。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2005)

  DOI：

  10.1002/ejoc.200400709

文献信息

• Probing Opioid Receptor Interactions with Azacycloalkane Amino Acids. Synthesis of a Potent and Selective ORL1 Antagonist
  作者：Liliane Halab、Jérôme A. J. Becker、Zsuzsanna Darula、Dirk Tourwé、Brigitte L. Kieffer、Frédéric Simonin、William D. Lubell

  DOI：10.1021/jm020078l

  日期：2002.11.1

  between conformation and biological activity of peptide ligands to the opioid receptor-like (ORL1) receptor. Three azabicyclo[x.y.0]alkane amino acids and a 5-tBuPro type VI beta-turn mimic were introduced into peptides 10-13 by solid-phase synthesis on MBHA resin. Biological examination of peptides 10-13 showed two new antagonists (10 and 12) exhibiting increased selectivity for the ORL1 receptor.

  氮杂环烷转向模拟物6-9用于研究肽配体对阿片样受体样（ORL1）受体的构象与生物学活性之间的关系。通过在MBHA树脂上进行固相合成，将三个氮杂双环[xy0]烷烃氨基酸和一个5-tBuPro VI型β转角模拟物引入到肽10-13中。肽10-13的生物学检查显示，两种新的拮抗剂（10和12）对ORL1受体的选择性增加。
• SECONDARY STRUCTURE STABILIZED NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Northwestern University

  公开号：US20160115197A1

  公开（公告）日：2016-04-28

  Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.

  本发明揭示了在调节NMDA受体活性方面具有增强效力的化合物。此类化合物可用于治疗学习、认知活动和镇痛等疾病和障碍，特别是在缓解和/或减轻神经病理性疼痛方面。
• Targeting the Prostaglandin F2α Receptor for Preventing Preterm Labor with Azapeptide Tocolytics
  作者：Carine B. Bourguet、Eugénie Goupil、Danaë Tassy、Xin Hou、Eryk Thouin、Felix Polyak、Terence E. Hébert、Audrey Claing、Stéphane A. Laporte、Sylvain Chemtob、William D. Lubell

  DOI：10.1021/jm200608k

  日期：2011.9.8

  The prostaglandin-F2 alpha (PGF2 alpha) receptor (FP) was targeted to develop tocolytic agents for inhibiting preterm labor. Azabicycloalkane and azapeptide mimics 2-10 were synthesized based on the (3S,6S,9S)-indolizidin-2-one amino acid analogue PDC113.824 (1), which was shown to modulate FP by a biased allosteric mechanism, involving both G alpha q- and G alpha 12-mediated signaling pathways, and exhibited significant tocolytic activity delaying preterm labor in a mouse model (Goupil; J. Biol. Chem. 2010, 285,25624-25636), Although changes in azabicycloalkane stereochemistry and ring size caused loss of activity, replacement of the indolizidin-2-one amino acid with azaGly-Pro and azaPhe-Pro gave azapeptides 6 and 8, which reduced PGF2 alpha-induced myometrial contractions, potentiated the effect of PGF2 alpha on G alpha q-mediated ERK1/2 activation, and inhibited FP modulation of cell ruffling, a response dependent on the G alpha 12/RhoA/ROCK signaling pathway. Revealing complementarities of azabicycloalkane and azapeptide mimics, novel probes, and efficient tocolytic agents were made to study allosteric modulation of the FP receptor.
• US9593145B2
  申请人：——

  公开号：US9593145B2

  公开（公告）日：2017-03-14